매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +13.2% 성장하면서 영업이익률이 11.7%에서 18.3%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +13.2%영업이익률 11.7%→18.3%FCF 33,735
Meta Biomed
A059210 · KOSDAQ₩3,685+1.24%
2026-08-03 closeMeta Biomed — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 295 건강관리 peers · not investment advice
Valuation in its own history
PER 4.62 · PBR 1.11 — own history (2008-04~) percentiles 100/100 · 90/100
PER100/100
PBR90/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 17 consecutive years · Raised 1 consecutive years · Yield 0.81% (based on 2025 payment of 30원) · 3-year growth +14.5%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 3.44
Distress
Grey
Safe
- Altman Z''
- 3.44
- Beneish M-Score
- -2.45
- Sloan accrual
- -0.13%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
7/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score7/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03건강관리
This stock is in 건강관리: revenue rank 122 of 290, share 0.2%.
122 / 2900.2%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6메타바이오메드0.2%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 269
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 18.3%
- Interest coverage
- 4.6x
- Return on equity (ROE)
- 24%
Operating margin −5pp
TolerableInterest coverageBase 4.6x adverse case 3.3x
Return on equity (ROE)Base 24% adverse case 9.4%
Revenue −15%
TolerableInterest coverageBase 4.6x adverse case 3.9x
Return on equity (ROE)Base 24% adverse case 11.7%
Interest rate +2pp
TolerableInterest coverageBase 4.6x adverse case 3.2x
Return on equity (ROE)Base 24% adverse case 12.6%
Interest coverage limit
Current margin 14.3ppInterest coverage limit at an operating margin of 4%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-06-29Suppliers disclosed by the company in its 2026-06-29 annual report.
Suppliers without disclosed amount
Financials at a glance
Meta Biomed's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 오석송22.82%2026-06-12 · 증감 -1.04%p
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
Recent filings
Meta Biomed's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy